Voyager Therapeutics (VYGR) Other Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics has reported Other Non-Current Liabilities for 11 years, with the latest figure at $39.4 million in Q3 2024.

• Quarterly Other Non-Current Liabilities rose 108.09% year-over-year to $39.4 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $39.4 million (up 108.09% YoY) and the FY2023 annual result came in at $18.1 million, down 15.03% from the prior year.
• Other Non-Current Liabilities declined to $39.4 million in Q3 2024 per VYGR's latest filing, from $41.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $44.4 million in Q4 2020 and troughed at $18.1 million in Q4 2023.
• A 5-year average of $31.9 million and a median of $31.1 million in 2020 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities tumbled 46.3% in 2022, then jumped 109.51% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $44.4 million in 2020, then dropped by 10.81% to $39.6 million in 2021, then plunged by 46.24% to $21.3 million in 2022, then declined by 15.03% to $18.1 million in 2023, then jumped by 117.57% to $39.4 million in 2024.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $39.4 million, $41.2 million, and $43.0 million for Q3 2024, Q2 2024, and Q1 2024 respectively.